| Date | Time | Source | Headline | Symbol | Company |
| 09/28/2007 | 6:04AM | Edgar (US Regulatory) | CV Therapeutics Inc (Other) (8-K) | NASDAQ:CVTX | CV Therapeutics (MM) |
| 09/27/2007 | 4:01PM | PR Newswire (US) | CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets) | NASDAQ:CVTX | CV Therapeutics (MM) |
| 09/26/2007 | 3:44PM | Edgar (US Regulatory) | CV Therapeutics Inc (Other) (4) | NASDAQ:CVTX | CV Therapeutics (MM) |
| 09/21/2007 | 10:51AM | Edgar (US Regulatory) | CV Therapeutics Inc (Other) (8-K) | NASDAQ:CVTX | CV Therapeutics (MM) |
| 09/21/2007 | 10:44AM | Edgar (US Regulatory) | CV Therapeutics Inc (Other) (8-K) | NASDAQ:CVTX | CV Therapeutics (MM) |
| 09/06/2007 | 6:02AM | Edgar (US Regulatory) | CV Therapeutics Inc - Current report filing | NASDAQ:CVTX | CV Therapeutics (MM) |
| 09/05/2007 | 2:30AM | PR Newswire (US) | Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R) | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/22/2007 | 7:00AM | PR Newswire (US) | CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/15/2007 | 7:00AM | PR Newswire (US) | Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI) | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/14/2007 | 7:00AM | PR Newswire (US) | CV Therapeutics Launches 1000 mg Ranexa(R) Tablet | NASDAQ:CVTX | CV Therapeutics (MM) |
| 08/07/2007 | 8:00AM | PR Newswire (US) | CV Therapeutics Reaffirms Financial Guidance | NASDAQ:CVTX | CV Therapeutics (MM) |
| 07/30/2007 | 4:01PM | PR Newswire (US) | CV Therapeutics Reports 2007 Second Quarter Financial Results | NASDAQ:CVTX | CV Therapeutics (MM) |
| 07/30/2007 | 7:00AM | PR Newswire (US) | CV Therapeutics Engages Renowned Investment Banker Frederick Frank to Provide Advisory Services | NASDAQ:CVTX | CV Therapeutics (MM) |
| 07/17/2007 | 4:01PM | PR Newswire (US) | CV Therapeutics to Announce 2007 Second Quarter Financial Results on Monday, July 30, 2007 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 07/16/2007 | 4:01PM | PR Newswire (US) | CV Therapeutics Names Lewis Stuart Senior Vice President, Commercial Operations | NASDAQ:CVTX | CV Therapeutics (MM) |
| 07/09/2007 | 4:01PM | PR Newswire (US) | CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa(R) | NASDAQ:CVTX | CV Therapeutics (MM) |
| 06/18/2007 | 5:01PM | PR Newswire (US) | CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 06/18/2007 | 10:31AM | PR Newswire (US) | Seven Summits Research Releases Alerts on AAPL, F, MRK, ICE, and CVTX | NASDAQ:CVTX | CV Therapeutics (MM) |
| 05/24/2007 | 7:30AM | PR Newswire (US) | CV Therapeutics Significantly Reduces Operating Expenses | NASDAQ:CVTX | CV Therapeutics (MM) |
| 05/14/2007 | 5:01PM | PR Newswire (US) | CV Therapeutics Submits New Drug Application For Regadenoson | NASDAQ:CVTX | CV Therapeutics (MM) |
| 05/03/2007 | 8:00AM | PR Newswire (US) | CV Therapeutics Announces Five Abstracts Accepted for Presentation at Annual Scientific Sessions of Heart Rhythm Society | NASDAQ:CVTX | CV Therapeutics (MM) |
| 04/24/2007 | 5:00PM | PR Newswire (US) | Journal of the American Medical Association Publishes MERLIN TIMI-36 Results | NASDAQ:CVTX | CV Therapeutics (MM) |
| 04/24/2007 | 5:00PM | PR Newswire (US) | CV Therapeutics Reports 2007 First Quarter Financial Results | NASDAQ:CVTX | CV Therapeutics (MM) |
| 04/18/2007 | 5:01PM | PR Newswire (US) | CV Therapeutics to Announce 2007 First Quarter Financial Results on Tuesday, April 24, 2007 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 03/14/2007 | 8:00AM | PR Newswire (US) | JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program | NASDAQ:CVTX | CV Therapeutics (MM) |
| 03/06/2007 | 4:01PM | PR Newswire (US) | CV Therapeutics Announces Topline MERLIN TIMI-36 Results | NASDAQ:CVTX | CV Therapeutics (MM) |
| 02/21/2007 | 7:00AM | PR Newswire (US) | CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 | NASDAQ:CVTX | CV Therapeutics (MM) |
| 02/12/2007 | 9:31AM | PR Newswire (US) | Seven Summits Research Releases Alerts on MSFT, MER, X, PALM, and CVTX | NASDAQ:CVTX | CV Therapeutics (MM) |
| 02/08/2007 | 4:01PM | PR Newswire (US) | CV Therapeutics Reports 2006 Fourth Quarter and Full Year Financial Results | NASDAQ:CVTX | CV Therapeutics (MM) |
| 02/07/2007 | 4:01PM | PR Newswire (US) | MERLIN TIMI-36 Study Accepted As Late Breaking Clinical Trial at American College of Cardiology Annual Scientific Session | NASDAQ:CVTX | CV Therapeutics (MM) |